Cereno Scientific’s CS585 program is granted patent in the US
Cereno Scientific (XSAT: CRNO B) today announced that the first patent in the company’s preclinical CS585 program has been granted by the US Patent Office (USPTO). The CS585 program is currently undergoing a 2-year preclinical development program in collaboration with the University of Michigan with the aim of a successful transition to a Phase I clinical program. The program comprises prostacyclin receptor agonists that have demonstrated potential to significantly improve on mechanisms relevant to selected cardiovascular diseases.
“It is very positive that the first patent has been obtained in the CS585 preclinical program. Receiving validation of the innovative nature of the research, which is a patent criterion, from one of the world’s largest patent offices is highly important in any stage of drug development. Our preclinical programs are key to the long-term success of Cereno, and a solid patent protection is a critical factor in a future commercialization of the drug candidates,” said Sten R. Sörensen, CEO at Cereno Scientific.
This first patent in the CS585 program is titled “Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents”, US11111222. It is issued by the USPTO and covers a key strategic market for Cereno, the US.
Cereno entered an option agreement for the CS585 program with the University of Michigan in March 2021, which provides Cereno with the exclusive rights to evaluate the program’s market potential. If the evaluation in the preclinical development program is successful, Cereno can exercise its option to exclusively in-license the drug including its intellectual property rights for further clinical development and commercialization.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.